Trial Profile

A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN2109 in Subjects With Unresectable or Metastatic Advanced Solid Tumors.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAN 2109 (Primary)
Indications Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Merkel cell carcinoma; Sarcoma; Skin cancer; Solid tumours
Focus Adverse reactions
Sponsors CanWell Pharma

Most Recent Events

31 Oct 2024 Status changed from not yet recruiting to recruiting.
02 Apr 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com